Bulletin
Investor Alert

Denali Therapeutics Inc.

NAS: DNLI

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Denali Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Feb 8, 2023, 4:40 p.m.

DNLI
/zigman2/quotes/200043077/composite

$

30.26

Change

-0.23 -0.75%

Volume

Volume 44,897

Quotes are delayed by 20 min

/zigman2/quotes/200043077/composite

Today's close

$ 31.96

$ 30.49

Change

-1.47 -4.60%

Day low

Day high

$30.44

$31.98

Open

52 week low

52 week high

$20.24

$39.43

Open

Company Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lav...

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Valuation

Price to Sales Ratio

111.38

Price to Book Ratio

5.67

Enterprise Value to EBITDA

-11.91

Enterprise Value to Sales

31.22

Efficiency

Total Asset Turnover

0.03

Liquidity

Current Ratio

2.37

Quick Ratio

2.37

Cash Ratio

2.29

Profitability

Gross Margin

88.47

Operating Margin

-607.78

Pretax Margin

-598.34

Net Margin

-597.15

Return on Assets

-19.32

Return on Equity

-27.51

Return on Total Capital

-26.34

Capital Structure

Total Debt to Total Assets

4.56

Officers and Executives

Name Age Officer Since Title
Dr. Ryan J. Watts 43 2013 President, Director & Chief Scientific Officer
Dr. Alexander O. Schuth 47 2013 Chief Operating Officer
Dr. Joe Lewcock - 2020 Chief Scientific Officer
Dr. Carole Ho 48 2015 Chief Medical Officer & Head-Development
Dr. Dana Andersen - 2018 CTO & Chief Manufacturing Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/17/2023 Alexander O. Schuth
COFO and Secretary 		114   Disposition at $29.87 per share. 3,405
01/17/2023 Alexander O. Schuth
COFO and Secretary 		9,886   Disposition at $29.53 per share. 291,933
01/17/2023 Alexander O. Schuth
COFO and Secretary 		10,000   Derivative/Non-derivative trans. at $5.28 per share. 52,800
01/09/2023 Carole Ho
Chief Medical Officer 		1,459   Disposition at $28.48 per share. 41,552
01/06/2023 Carole Ho
Chief Medical Officer 		1,451   Disposition at $28.67 per share. 41,600
01/05/2023 Ryan J. Watts
President and CEO; Director 		4,800   Disposition at $28.44 per share. 136,512
01/05/2023 Steve E. Krognes
Director 		2,970   Disposition at $28.44 per share. 84,466
01/05/2023 Alexander O. Schuth
COFO and Secretary 		2,636   Disposition at $28.44 per share. 74,967
01/05/2023 Carole Ho
Chief Medical Officer 		2,636   Disposition at $28.44 per share. 74,967
01/04/2023 Ryan J. Watts
President and CEO; Director 		5,029   Disposition at $28.73 per share. 144,483
01/04/2023 Alexander O. Schuth
COFO and Secretary 		2,912   Disposition at $28.7 per share. 83,574
01/04/2023 Alexander O. Schuth
COFO and Secretary 		2,912   Disposition at $28.7 per share. 83,574
01/04/2023 Carole Ho
Chief Medical Officer 		2,913   Disposition at $28.69 per share. 83,573
01/03/2023 Ryan J. Watts
President and CEO; Director 		82,240   Award at $0 per share. 0
01/03/2023 Alexander O. Schuth
COFO and Secretary 		41,120   Award at $0 per share. 0
01/03/2023 Carole Ho
Chief Medical Officer 		41,120   Award at $0 per share. 0
11/23/2022 Marc Tessier-Lavigne
Director 		20,000   Disposition at $30.48 per share. 609,600
11/02/2022 Marc Tessier-Lavigne
Director 		11,252   Disposition at $30.33 per share. 341,273
11/01/2022 Marc Tessier-Lavigne
Director 		8,748   Disposition at $30.2 per share. 264,189
10/07/2022 Alexander O. Schuth
COFO and Secretary 		20,000   Derivative/Non-derivative trans. at $0.68 per share. 13,600
/news/latest/company/us/dnli

MarketWatch News on DNLI

  2. Denali Therapeutics stock price target cut to $41 from $60 at Stifel Nicolaus

    7:58 a.m. March 2, 2022

    - Tomi Kilgore

  4. 4 Beaten-Down Biotech Stocks That Could Take Off

    3:07 p.m. Nov. 17, 2021

    - Barron's Online

  5. Denali Therapeutics started at outperform with $85 stock price target at Oppenheimer

    6:16 a.m. Sept. 21, 2021

    - Tomi Kilgore

  6. Biogen's Alzheimer's Drug Is Approved by the FDA

    1:02 p.m. June 7, 2021

    - Barron's Online

  8. Don’t Expect Amazon Prime Day to Move the Stock

    7:26 a.m. June 2, 2021

    - Barron's Online

  9. The FDA's Biogen Decision Will Cause Waves Across Biotech

    8:20 p.m. June 1, 2021

    - Barron's Online

  10. Denali Therapeutics started at buy with $70 stock price target at UBS

    8:03 a.m. May 18, 2021

    - Tomi Kilgore

  11. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  12. The 12 Most Overpriced Stocks in America

    7:48 a.m. Dec. 28, 2020

    - Barron's Online

  14. Denali down 10% on pause in neurological drug

    4:53 p.m. June 9, 2020

    - MarketWatch.com

  15. Panic Takes Hold

    7:39 p.m. March 12, 2020

    - Barron's Online

  16. Denali Therapeutics upgraded to outperform from neutral at Wedbush

    8:05 a.m. Feb. 28, 2020

    - Tomi Kilgore

  17. Denali Therapeutics started at hold with $26 stock price target at Stifel Nicolaus

    7:40 a.m. Feb. 19, 2020

    - Tomi Kilgore

  18. Denali Therapeutics started at neutral with $19 stock price target at Wedbush

    7:22 a.m. Sept. 26, 2019

    - Tomi Kilgore

  19. Denali Therapeutics started at buy with $35 stock price target at Instinet

    7:35 a.m. Sept. 13, 2019

    - Tomi Kilgore

  20. Jeffrey Epstein’s Investing Lagged Behind the Market

    12:23 p.m. July 17, 2019

    - Barron's Online

  21. Loading more headlines...
/news/nonmarketwatch/company/us/dnli

Other News on DNLI

  4. 10-Q: DENALI THERAPEUTICS INC.

    3:12 p.m. Nov. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  6. Tracking Baillie Gifford's 13F Portfolio - Q3 2022 Update

    5:10 a.m. Oct. 31, 2022

    - Seeking Alpha

  8. Clarius Group, LLC Buys 3, Sells 2 in 3rd Quarter

    4:00 p.m. Oct. 24, 2022

    - GuruFocus.com

  9. Denali Therapeutics prices $275M stock offering

    3:56 a.m. Oct. 20, 2022

    - Seeking Alpha

  15. Baron Growth Fund Q2 2022 Shareholder Letter

    3:20 a.m. Aug. 11, 2022

    - Seeking Alpha

  16. 3 Companies Growing Revenue Fast

    12:23 p.m. Aug. 10, 2022

    - GuruFocus.com

  19. 10-Q: DENALI THERAPEUTICS INC.

    3:12 p.m. Aug. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  21. Loading more headlines...

At a Glance

Denali Therapeutics, Inc.

161 Oyster Point Boulevard

San Francisco, California 94080

Phone

1 6158668548

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$48.66M

Net Income

$-290.58M

Employees

380.00

Annual Report for DNLI

/news/pressrelease/company/us/dnli

Press Releases on DNLI

  3. Denali Slumps on Drug Candidate Tests

    10:12 a.m. Dec. 5, 2022

    - Baystreet.ca

  9. Denali Therapeutics Announces Proposed Offering of Common Stock

    3:41 p.m. Oct. 18, 2022

    - GlobeNewswire

  21. Loading more headlines...
Link to MarketWatch's Slice.